Veracyte (VCYT) Q2 2026 Earnings: Margin Deepening, Decipher Growth, and Medicare’s TrueMRD Moment

Veracyte, the cancer diagnostics player trading as VCYT on Nasdaq, delivered a solid Q2 2026. Total revenue rose to $150.3 million, up 15% year over year, fueled by strength in Decipher and Afirma testing. The company also showcased margin expansion, a sturdy cash position, and strategic product launches that could shape the back half of the year. On the earnings front, GAAP net income came in at $25.5 million (about 17% of revenue) and adjusted EBITDA reached $44.0 million (roughly 29% of revenue). Yet the release draws a line under a traditional EPS figure, inviting investors to compute per-share impact once share counts are applied and to watch the conference call for any future guidance or EPS consensus discourse.

Overview: Growth Engines in Fragile Times

The quarter underscores durable demand for Veracyte’s core testing portfolio. Total revenue of $150.3 million represents a clean 15% leap from the prior year’s period, with testing revenue at $145.7 million, up 19%. Decipher, the company’s prognostic and predictive testing line, grew 20% to $91.9 million, while Afirma rose 18% to $51.2 million. Volume stats reinforce the story: total tests climbed 13% to 50,967; testing volume rose 14% to 48,389; Decipher tests cited a roughly 17% increase to about 29,700, and Afirma tests around 18,600.

On the profitability side, GAAP net income of $25.5 million equates to 17.0% of revenue, and non-GAAP (adjusted) EBITDA was $44.0 million, or 29.2% of revenue. The company also generated cash from operations of $45.8 million, leaving Veracyte with about $485.2 million in cash, cash equivalents, and short-term investments as of June 30, 2026. Management emphasizes margin discipline alongside growth, with total gross margin at 72% and non-GAAP gross margin at 75% for the quarter.

Product and portfolio progress mattered as well. Veracyte launched the Prosigna Breast Test in the U.S. for early-stage HR+ breast cancer and rolled out TrueMRD for muscle-invasive bladder cancer (MIBC). The TrueMRD test secured Medicare coverage—the first for the whole-genome sequencing–based TrueMRD platform—potentially expanding payer support and patient access. In parallel, the company highlighted continued clinical evidence expansion, including OPTIMA and ENZAMET trial signals that bolster the credibility of Decipher and Afirma. The quarter also featured broad scientific dissemination, with nearly 60 abstracts and presentations across Decipher and Afirma portfolios.

Financial Highlights

• Total revenue: $150.3 million, up 15% YoY
• Testing revenue: $145.7 million, up 19% YoY
• Decipher revenue: $91.9 million, up ~20% YoY
• Afirma revenue: $51.2 million, up ~18% YoY
• Total tests: 50,967, up 13%
• Testing tests: 48,389, up 14%
• GAAP net income: $25.5 million (17.0% of revenue)
• Adjusted EBITDA: $44.0 million (29.2% of revenue)
• Cash from operations: $45.8 million
• Cash, cash equivalents, and short-term investments: $485.2 million (as of 6/30/2026)
• Gross margin: 72% (GAAP); Non-GAAP gross margin: 75%

Operational Highlights and Product Milestones

Veracyte’s quarter centers on the integration of new products and payer progress. Prosigna LDT and TrueMRD for MIBC expand the addressable customer base and clinical utility, while Medicare coverage for TrueMRD addresses a meaningful reimbursement milestone. The Prosigna Breast Test rollout in the U.S. supports the company’s strategy to broaden into earlier-stage breast cancer risk stratification. The company’s emphasis on real-world evidence—through the OPTIMA trial and ENZAMET trial data—helps bridge clinical utility with payer acceptance, a perennial challenge in diagnostics.

From a growth perspective, the balance of Decipher, Afirma, and product fronthaul suggests Veracyte is not a one-test shop. The combined strength in ground-to-cloud workflow (test volume and multi-product portfolios) signals resilience even if a single product faces headwinds. And for readers tracking earnings cadence, the absence of a disclosed EPS figure in the release means investors will need to read between the lines on per-share implications, or wait for the call for EPS consensus discussion and any potential earnings surprise signals relative to street expectations.

Non-GAAP and The Note on Non-GAAP Measures

A reconciliation of GAAP to non-GAAP financial measures is provided in the press materials, with an explicit note on using non-GAAP figures. The company reiterates these measures to facilitate comparisons and highlight operating performance after adjusting for certain items. As usual in this space, observers will monitor how these adjustments influence the apparent margin profile and whether the bar for a future revenue forecast or profitability targets shifts in the months ahead.

Market Implications: What This Might Portend

The Q2 print reinforces a theme in the diagnostics arena: strong demand for actionable molecular testing, and a push to monetize new capabilities via payer coverage and regulatory pathways. Veracyte’s margin expansion amid revenue growth points to operating leverage—an encouraging sign for investors eyeing durable profitability in a period of cost discipline across the sector.

For sector peers, the Medicare coverage milestone for TrueMRD could set a benchmark for other whole-genome sequencing–based panels seeking payer recognition. If the reimbursement tailwinds persist, peers with complementary tests in oncology may accelerate investments in evidence generation and clinical utility, hoping to translate test volume gains into improved margin profiles.

In terms of equity story, the EPS dimension remains a function of share count and non-GAAP adjustments. The absence of a disclosed EPS figure in the release leaves EPS consensus and potential earnings surprise dynamics to be settled on the conference call and in subsequent filings. Still, the trajectory—revenue growth led by Decipher and Afirma, plus robust cash flow—keeps Veracyte in the talking points of investors who chase growth with a side of margin expansion.

Outlook and Takeaways

The company did not publish a formal revenue forecast in this release, leaving guidance-forecasters to parse the trajectory of Decipher and Afirma growth, as well as the adoption rate of Prosigna LDT and TrueMRD in the Medicare environment. The hardware of the business—steady testing volumes, expanding clinical evidence, and payer progress—should sustain revenue momentum into the second half of 2026, provided reimbursement remains supportive and the testing mix does not tilt unfavorably.

Analysts and investors will be listening for two things on the upcoming call: (1) a quantified read on the EPS impact per share after accounting for the company’s capital structure, and (2) any forward-looking revenue forecast or guidance that could anchor expectations for the rest of the year. In the meantime, Veracyte’s Q2 show—margin strength, cash generation, and product diversification—reads like a company that plans to monetize clinical validation as fast as it validates it.

Conclusion: A Quarter That Aligns Growth and Gravity

Veracyte’s Q2 2026 results demonstrate an company narrative that is more than just a storyline about tests; it’s about portfolio balance, payer progress, and a cash-rich balance sheet that could sustain investments in clinical utility and new product modalities. The presence of a Medicare-supported TrueMRD, plus the Prosigna and Decipher growth engines, paints a picture of a company that is simultaneously expanding its addressable market and strengthening its financial backbone. As investors weigh EPS implications and await the EPS consensus on the next earnings call, Veracyte offers a case study in how medical diagnostics firms can balance top-line momentum with capital discipline while hedging against reimbursement risk—and perhaps teaching the rest of the sector a few things about the art of the quarterly update.